{"title":"Multi-Omics Integration Reveals Incomplete Reactivation of Developmental Cell-Cycle Programs in Adult Human Infarcted Hearts","authors":"Jieran Lyu, Yuki Kuramoto, Jun Li, Jong-Kook Lee, Kyoko Hidaka, Yasushi Sakata","doi":"10.1111/cbdd.70337","DOIUrl":null,"url":null,"abstract":"<p>Adult human hearts show limited regeneration after acute myocardial infarction (AMI) despite a small subpopulation (~5%) of cardiomyocytes re-entering the cell cycle. We integrated public single-nucleus RNA-seq, spatial transcriptomics, bulk RNA-seq and ATAC-seq datasets from human fetal hearts and adult infarcted hearts to investigate why cell-cycle-active cardiomyocytes fail to complete division. These cells were enriched in the infarct zone (IZ) and activated early cell-cycle programs, but showed insufficient reactivation of late mitotic and cytokinesis execution machinery, particularly <i>ANLN</i> and <i>KIF18A</i>, and instead engaged stress-adaptive programs. Multi-omics filtering across expression, chromatin accessibility, and co-expression/regulatory networks highlighted five developmental cell-cycle-associated genes with insufficient adult reactivation: <i>ANLN</i>, <i>KIF18A</i>, <i>MDK</i>, <i>RTKN2</i>, and <i>SOX11</i>. In human induced pluripotent stem cell-derived cardiomyocytes, hypoxia suppressed most candidates, whereas <i>MDK</i> retained responsiveness to pro-proliferative Wnt stimulation. These findings suggest that incomplete cytokinesis reactivation represents a key bottleneck for adult human cardiac regeneration, and nominate <i>MDK</i> as a tractable candidate for chemical biology and drug-discovery efforts aimed at promoting cardiomyocyte cell-cycle completion.</p>","PeriodicalId":143,"journal":{"name":"Chemical Biology & Drug Design","volume":"107 6","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cbdd.70337","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chemical Biology & Drug Design","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cbdd.70337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Adult human hearts show limited regeneration after acute myocardial infarction (AMI) despite a small subpopulation (~5%) of cardiomyocytes re-entering the cell cycle. We integrated public single-nucleus RNA-seq, spatial transcriptomics, bulk RNA-seq and ATAC-seq datasets from human fetal hearts and adult infarcted hearts to investigate why cell-cycle-active cardiomyocytes fail to complete division. These cells were enriched in the infarct zone (IZ) and activated early cell-cycle programs, but showed insufficient reactivation of late mitotic and cytokinesis execution machinery, particularly ANLN and KIF18A, and instead engaged stress-adaptive programs. Multi-omics filtering across expression, chromatin accessibility, and co-expression/regulatory networks highlighted five developmental cell-cycle-associated genes with insufficient adult reactivation: ANLN, KIF18A, MDK, RTKN2, and SOX11. In human induced pluripotent stem cell-derived cardiomyocytes, hypoxia suppressed most candidates, whereas MDK retained responsiveness to pro-proliferative Wnt stimulation. These findings suggest that incomplete cytokinesis reactivation represents a key bottleneck for adult human cardiac regeneration, and nominate MDK as a tractable candidate for chemical biology and drug-discovery efforts aimed at promoting cardiomyocyte cell-cycle completion.
期刊介绍:
Chemical Biology & Drug Design is a peer-reviewed scientific journal that is dedicated to the advancement of innovative science, technology and medicine with a focus on the multidisciplinary fields of chemical biology and drug design. It is the aim of Chemical Biology & Drug Design to capture significant research and drug discovery that highlights new concepts, insight and new findings within the scope of chemical biology and drug design.